Pharma Mulls Drug Launch Delays Amid ‘Most Favored’ Prices (Law360 Healthcare Authority)
The Trump administration’s efforts to cajole drug companies to align U.S. drug prices to lower prices charged overseas is producing unintended consequences. In some cases, drugmakers are even weighing taking existing drugs off of certain markets to avoid seeing their domestic prices slashed. In recent months, Heath Ingram, a healthcare partner at Goodwin who works with small and midsize drugmakers, said that many of his drugmaker clients have come to him, asking for advice on whether they should consider pulling a product from a country that would be subject to MFN pricing. One client in particular is seriously considering pulling its product from France, he said. “There just isn’t enough patient demand for their product in France to justify continuing to sell [there],” he said. Drug companies already selling products overseas and looking at the US market are also considering delays.
Ingram said he’s talked with several European pharmaceutical companies with rare-disease treatments who are now hesitating to sell in the US because it would mean having to navigate MFN pricing. “So we are sort of creating a distortion in the global biomedical innovation system by MFN, a distortion that … folks have to weigh,” he said. “Ultimately, all of this is creating a distortion of who has access to the latest and greatest medicine.”
Read the Law360 article for more.